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Abstract
We developed a semi-automated active monitoring system that uses sequential matched-cohort
analyses to assess drug safety across a distributed network of longitudinal electronic healthcare
data. In a retrospective analysis, we showed that the system would have identified cerivastatin-
induced rhabdomyolysis. In this study, we evaluated whether the system would generate alerts for
three drug-outcome pairs: rosuvastatin and rhabdomyolysis (known null association), rosuvastatin
and diabetes mellitus, and telithromycin and hepatotoxicity (two examples for which alerting
would be questionable). During >5 years of monitoring, rate differences (RDs) comparing
rosuvastatin to atorvastatin were -0.1 cases of rhabdomyolysis per 1,000 person-years (95% CI,
-0.4, 0.1) and -2.2 diabetes cases per 1,000 person-years (95% CI, -6.0, 1.6). The RD for
hepatotoxicity comparing telithromycin to azithromycin was 0.3 cases per 1,000 person-years
(95% CI, -0.5, 1.0). In a setting in which false positivity is a major concern, the system did not
generate alerts for three drug-outcome pairs.
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tINTRODUCTION
With the ongoing development of the US Food and Drug Administration’s Sentinel
Initiative (1), and similar systems around the world, near-real-time active medical product
safety monitoring may soon be a reality. These systems will enable regulators and other
stakeholders to monitor outcomes of medical product use in distributed data networks
comprising healthcare utilization data for many millions of patients (2). The amount of data
contained in such systems raises concerns that the systems will generate intractable numbers
of false positive alerts for purely statistical reasons (3). The non-randomized data that will
feed these systems are collected in routine care and may therefore signal relations that arise
from medical perceptions or administrative constraints rather than from biology, raising the
additional specter of systematic false positive findings (4,5).
The challenges inherent in a broad-based monitoring system are similar to those confronted
in every pharmacoepidemiologic study, and a system that incorporates sound design and
analysis may reduce false positive signals. We have developed a semi-automated,
sequential, propensity-score matched cohort approach (6) to drug safety monitoring built on
validated methods for drug safety research and that can be easily deployed in distributed
data networks (7,8). The approach involves: (1) identifying new users of a medical product;
(2) matching them by propensity score to new users of a comparator product; (3) tabulating
results across the distributed databases; and (4) applying an automated alerting algorithm
selected from an earlier simulation study (9).
Had this system been in place at the time, it would have identified cerivastatin-induced
rhabdomyolysis in longitudinal electronic healthcare data as early as a year before the drug
was withdrawn from the US market (9). Given the concerns about statistical and systematic
false positivity, we expanded the application of the approach to three additional examples
including one in which we did not expect an alert (rosuvastatin and rhabdomyolysis), and
two examples for which we were not certain whether alerting would be expected –
telithromycin and hepatotoxicity, and rosuvastatin and diabetes mellitus. We describe what
would have occurred had this system been in place at the time of US market approval of
each drug.
RESULTS
Rosuvastatin and the risks of rhabdomyolysis and diabetes mellitus
Over more than five years of monitoring, we observed 8 cases of rhabdomyolysis among
57,998 propensity score-matched rosuvastatin and atorvastatin pairs who contributed a total
of 45,571 person-years of follow-up (Figure 1). Two of the 8 rhabdomyolysis cases occurred
among rosuvastatin-treated patients, resulting in a difference at the end of monitoring of -0.1
(95% CI, -0.4, 0.1) events per 1,000 person-years and a corresponding rate ratio of 0.4 (95%
CI, 0.1, 1.9). None of the three selected algorithms generated alert in this example.
Among similar follow-up times for the diabetes outcome, we observed 859 incident diabetes
diagnoses among rosuvastatin-treated patients as compared to 1,055 among atorvastatin-
treated patients, resulting in a rate difference at the end of monitoring of -2.2 (95% CI, -6.0,
1.6) events per 1,000 person-years (Figure 2) and a corresponding rate ratio of 0.9 (95% CI,
0.9, 1.0). None of the selected algorithms generated alerts for this outcome either.
Telithromycin and risk of hepatotoxicity
We identified and matched 106,658 initiators of telithromycin to the same number of
initiators of azithromycin over more than 5 years of monitoring following telithromycin
marketing authorization. The 106,658 matched pairs contributed a total of 17,720 and
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t17,416 person-years of follow-up to the telithromycin and azithromycin groups, respectively
(Figure 3). We observed 41 cases of hepatotoxicity during follow-up, of which 23 (56%)
occurred among telithromycin-treated patients. None of the three selected algorithms
generated an alert. The rate difference at the end of monitoring was 0.3 (95% CI, -0.4, 1.0)
events per 1,000 person-years and the rate ratio was 1.3 (95% CI, 0.7, 2.3).
DISCUSSION
The proposed approach to active drug safety monitoring in electronic healthcare data, which
combines semi-automated procedures and some expert inputs, previously detected
cerivastatin-induced rhabdomyolysis, a known rare safety issue, as much as a year before the
drug was withdrawn from the market. That the system detected this known drug safety issue
provides some reassurance that it performs according to expectation. In the present
application, the system did not generate alerts for rosuvastatin and rhabdomyolysis, a
presumed true negative, or for two examples for which existing evidence is equivocal. False
alerting is a major concern in emerging active medical product surveillance systems that will
include data on many millions of patients. False positives, as well as false negatives, can
arise from many sources including chance but, more importantly in observational data, from
biases such as confounding by indication. Our approach to active monitoring is designed to
mitigate such biases, by relying on new users, active comparators, and PS-matching, in order
to minimize the number of false positive and false negative signals from the outset, before
they can have adverse public health consequences.
Around the time that FDA authorized rosuvastatin for marketing in the US, concern had
been raised regarding its associated with an elevated risk of rhabdomyolysis as compared to
other available statins. In particular, development of the highest dose rosuvastatin tablets
was discontinued because of an unacceptable increase in risk of rhabdomyolysis (10).
However, the potential association between rosuvastatin and rhabdomyolysis has been
evaluated in many post-marketing studies, none of which have found an elevated risk above
and beyond that conferred by other available statins (11–15). Given the concern about false
positivity in medical product safety monitoring systems that will monitor myriad products
and outcomes among many millions of patients, our finding of a true negative is again
reassuring.
Recently, concern has been raised about whether statins increase patients’ risk of developing
type 2 diabetes mellitus. A meta-analysis of 13 randomized trials comprising 91,140
participants found that, over a mean follow-up of 4 years, statins were associated with a 9%
increase in odds of diabetes as compared to placebo or no treatment (16). Another meta-
analysis reported similar findings and that any effect of statins on diabetes is likely a class
effect (17). Because we compared new users of rosuvastatin to new users of atorvastatin, our
safety monitoring question is one of comparative, rather than absolute, safety. Consistent
with the meta-analyses, the system did not identify a higher risk of diabetes among patients
treated with rosuvastatin as compared to patients treated with atorvastatin. However, we did
not assess whether the system would have identified the small diabetes risk associated with
statins versus no treatment. Subsequent monitoring activities could explore the relative
safety of statins on diabetes as compared to other drugs to treat dyslipidemia, such as
ezetimibe.
Evidence is mixed regarding whether telithromycin increases the risk of hepatotoxicity
relative to similar antibiotic agents. A 2001 FDA advisory committee voted against approval
of telithromycin primarily because of concern about hepatotoxicity. Following the
completion of a controversial trial, FDA approved telithromycin in 2004 stating that the
frequency and severity of hepatotoxicity with telithromycin was similar to that of other
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tmacrolides (18). Through April 2006, FDA received 42 cases of telithromycin-associated
liver injury to its Adverse Event Reporting System (19). Post hoc analyses of the
spontaneous reports detected an association between telithromycin and reports of liver
injury, including mild disorders up to fulminant hepatotoxicity (20,21). However, neither of
two epidemiological studies that each included more than 100,000 initiators of
telithromycin, found evidence to suggest that telithromycin increases risk of hepatotoxicity
as compared to other macrolides (22). Telithromycin remains on the market in the US,
carrying only a labeled warning about hepatotoxicity, but not a black box warning (23).
Our system did not generate alerts for telithromycin. Again, we used an active comparator,
which reformulates the monitoring question to one of comparative safety. These findings
from our system are compatible with those of the other two large post-marketing database
studies. While the system did not generate alerts, the results also cannot rule out a small
increased incidence of hepatotoxicity associated with telithromycin as compared to
azithromycin. At the end of the monitoring timeframe, the incidence rate of hepatotoxicity
was 1.3 events per 1,000 person-years in the telithromycin group and 1.0 events per 1,000
person-years in the azithromycin group, corresponding to a rate difference of 0.3 (95% CI,
-0.5 to 1.0) events per 1,000 person-years and an incidence rate ratio of 1.3 (95% CI, 0.7 to
2.3). Although it is unclear whether the system’s lack of alerting in this example represents a
true or false negative, this example highlights an important benefit of active monitoring
systems, such as Sentinel. Even in the absence of an alert, active monitoring systems will
provide useful, continuous decision support at low cost since secondary data are captured
routinely and in near-real-time and analyses can be performed sequentially in an automated
fashion.
Our sequential PS-matched cohort framework for active drug safety monitoring offers
several advantages when focusing on pre-specified outcomes that may be related to medical
products. As illustrated by the rosuvastatin examples, PS-matched cohorts easily enable
monitoring of multiple outcomes per product. In addition, new-user cohort construction, PS
estimation, and matching procedures can be largely automated (24). Balancing observed pre-
treatment confounders via PSs separately in each database also simplifies data aggregation
across multiple data sources while obviating privacy concerns (7,8). In a drug’s early market
phase, there is usually an abundance of users of an active comparator relative to users of the
monitoring drug, offering sufficient opportunity to successfully match almost all patients
exposed to the newly marketed drug. Resulting estimates of association then pertain to the
effect observed among those exposed to the monitoring product as compared to the effect
that would have been observed had those exposed to the monitoring product actually been
exposed to the comparator agent. In addition, PS-matching enables monitoring of simple
marginal event rates between matched groups as the groups have been balanced on a large
number of potential confounders (25). Event rates can be expressed as observed (i.e. rate in
the new drug group) and expected (i.e. rate in the comparator group), which allows for direct
estimation of both absolute and relative measures of association and simplifies the
application of a broad range of alerting algorithms without the need for further regression
adjustment.
We encountered several practical limitations in implementing our approach in the four
examples. Because we began monitoring upon each drug’s market entry, we identified few
new users of the new drug during the first few month after the product was launched, which
precluded us from fitting large PS models in the first quarters. As a simple solution, we
combined the first two quarters to create the first monitoring period. While this enabled us to
fit PS models in data from the first two quarters, it necessarily delayed the time to earliest
possible alerting. However, it is unlikely that among few exposed patients there would be a
sufficient number of events to generate an alert. In addition, while many aspects of an active
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tmonitoring system can be automated, human inputs remain critical elements to any public
health surveillance activity. As in any pharmacoepidemiology study, our system requires
stakeholders to choose a comparison group, eligibility and exclusion criteria, and exposure,
follow-up, and outcome definitions. The assumptions made in each of these decisions will
have bearing on the system’s performance. For example, choosing a truly unexposed
comparison group, rather than a group exposed to an active comparator, allows stakeholders
to assess the absolute safety of a medical product, but also increases the opportunity for false
positive and false negative alerts due to increased confounding by indication (26).
Known limitations of electronic healthcare data pose challenges for broad application of
Sentinel-like systems. Data on many types of adverse drug events, such as rashes, allergic
reactions, and headaches, may not be fully captured in these data and the validity of codes
used to identify other events, such as seizures that do not result in emergency care, may be
questionable. Further, bias due to residual confounding is difficult to rule out since
electronic healthcare data often lack information on potential confounding variables,
including smoking status, body mass index, functional status, frailty, and over-the-counter
drug use. If, for example, clinicians preferentially prescribed telithromycin to sicker patients,
the resulting population imbalances might not be fully adjusted using health insurance
claims data, leading to residual confounding and a false positive alert. That the system did
not generate an alert in this example provides some reassurance that confounding has been
adequately addressed in this case. Finally, many facets of prospective medical product
monitoring require further exploration, methods development, and testing. However, as our
four examples to date suggest, active drug safety monitoring grounded in sound
epidemiologic theory and application and appropriate clinical rationale can produce valid
results despite conjecture to the contrary (27).
In summary, using examples we demonstrated the viability of a sequential PS-matched
cohort approach to active monitoring that integrates clinical, epidemiological, and other
expert stakeholder input with several semi-automated processes. In broad-based safety
surveillance systems, false positivity is a major concern. Our system previously generated
timely alerts about a known association, did not generate alerts for a known null association,
and did not produce alerts in the other two examples for which alerting would be
questionable.
METHODS
Data sources
We used data from three different sources to mimic monitoring across Sentinel’s distributed
data network: (1) the HealthCore Integrated Research Database (HIRD); (2) New Jersey
Medicare Parts A and B data linked to the Pharmacy Assistance for the Aged and Disabled
(PAAD) program; and (3) Pennsylvania Medicare data linked to the Pharmaceutical
Assistance Contract for the Elderly (PACE) program. The HIRD contains longitudinal
claims data comprising all filled prescriptions and clinical encounters from 14 Blue Cross
and/or Blue Shield licensed health plans in the northeastern, southeastern, mid-Atlantic,
mid-western, and western regions of the US. Starting in the third quarter of 2004, the
amount of HIRD data increased substantially as data from more plans became available.
Both PACE and PAAD provide medications at minimal expense to patients aged 65 and
older with low income but who do not meet the Medicaid annual income threshold. The
Medicare Parts A and B data include hospital discharge information and all fee-for-service
charges, with vital status information from the Social Security Administration’s Death
Master File. We included PACE- and PAAD-linked Medicare data only through the end of
2005.
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Sequential matched cohort monitoring framework
We replicated prospective monitoring as if new data became available on a quarterly basis.
We divided each database into sequential data sets defined by claims occurring in each
calendar quarter and queried each data set to identify all new users of each of the drugs of
interest and of their active comparators. We applied eligibility and exclusion criteria for
each example as described below (28). Within each data set, we constructed separate
propensity score (PS) models and used the PS to match new users of the monitoring drugs to
new users of the active comparator drugs in a 1:1 ratio. We used the 180 days preceding
each patient’s date of drug initiation (index date) to identify variables for the PS models,
which included a set of pre-defined potential confounders for each example (listed below)
plus potential confounders identified using the high-dimensional PS (hdPS) algorithm (29)
with its small sample option (v2, hdpharmacoepi.org; 30). In each model, we considered up
to 100 empirically-identified potential confounders from each of three domains – procedure
codes, diagnosis codes, and drugs used. Patients exposed to the monitoring drugs and the
comparators could only be matched if their index dates occurred in the same quarterly data
set.
Data pooling and follow-up
In each sequential data set, we identified outcomes for PS-matched patients who remained
under follow-up, as defined below for each example. We combined the exposure, outcome,
and follow-up time information for each calendar quarter across the three databases. This
approach to pooling across a distributed data network enables multivariable-adjusted
analyses while maintaining data privacy (7,8). These data elements served as inputs into the
alerting algorithms. For example, inputs from the first period included the number of
matched pairs with index dates in the first calendar quarter, the number of outcomes in each
exposure group, and the total follow-up time in each group through the end of the first
period. The algorithm inputs from the second period included the same corresponding data
for new users with index dates in the second calendar quarter plus additional follow-up and
outcome data for patients with index dates in the first period whose follow-up continued into
the second period (Appendix Figure 1). Because relatively few patients use a new drug when
it first enters the market, we combined the first two calendar quarters in which prescriptions
for the new drug began to appear in the databases to create the first monitoring period in
each example.
Algorithm selection and application
Alerting algorithms refer to sequential statistical monitoring approaches, such as group
sequential monitoring methods and sequential probability ratio tests, that could be used for
medical product safety monitoring. In a statistical simulation study, we found that the
relative performance of algorithms, with respect to the accuracy and timeliness of alerting,
in the setting of prospective safety monitoring varied substantially depending on the
characteristics of specific scenarios (9). In the Appendix we provide the list of algorithms
(Appendix Table) that we tested in the simulation study along with their relative
performances under varying parameter constellations (Appendix Figure 2). The relative
performance of the algorithms depended on event frequency and on user preference for
identifying potential safety issues with high sensitivity versus high specificity. We used the
results of the simulation study to select three algorithms for each example, based on three
values for preference for sensitivity versus specificity that regulators may define (31). To
select the algorithms, we estimated the expected number of events based on the number of
exposed patients observed in the first two calendar quarters (assuming that utilization of the
drug would increase in each period) and on literature estimates of the incidence of each
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toutcome. The selected algorithms and their operating characteristics from the simulation
study are presented in Table 1. Additional operating characteristics of the 93 algorithms
tested in 600,000 simulated scenarios are available from the authors.
Specifics of each example
Rosuvastatin and rhabdomyolysis and diabetes mellitus—We selected
atorvastatin as an active comparator because it was available on the market before the
introduction of cerivastatin and it has low risk of rhabdomyolysis (32). We defined new
users of rosuvastatin or atorvastatin as no use of any statin in the 180 days preceding the
index date. We excluded patients with evidence of diabetes, myopathy, renal dysfunction, or
liver disease prior to the index date. We used the same sequential PS-matched cohorts for
both rhabdomyolysis and diabetes mellitus outcomes. In addition to age and sex, we
included in the PS models risk factors for rhabdomyolysis including hypothyroidism and use
of drugs that either cause or interact with statins to cause rhabdomyolysis (33) plus the
following diabetes risk factors: coronary artery disease, congestive heart failure,
hemorrhagic stroke, hypertension, dyslipidemia, peripheral vascular disease, and use of
angiotensin converting enzyme inhibitors, beta-blockers, non-statin cholesterol-lowering
drugs, ticlopidine, clopidogrel, and nitrates.
We followed patients for rhabdomyolysis from their index dates until they experienced the
event, discontinued their index treatment (as defined by a gap in treatment of greater than 14
days), switched to a different statin, died, or disenrolled. We defined rhabdomyolysis using
the algorithm for claims data validated by Andrade et al, which had a positive predictive
value of 74% in a network of managed care organization databases (34). For diabetes
monitoring, we followed patients until they received a diagnosis of diabetes, discontinued
their index treatment (plus a 60-day grace period added to the end of the days supply of the
last prescription), switched to a different statin, died, or disenrolled. We defined diabetes
using a validated algorithm for claims data, which has been found to have a positive
predictive value of 97% (35).
Telithromycin and hepatotoxicity—We defined new use of telithromycin or
azithromycin – an active comparator that shares similar indications as telithromycin, was
available at the time of telithromycin approval, and was commonly used – as no prior use of
either drug in the 180 days preceding the index date. We excluded patients with evidence of
hepatic injury or impairment, including those with diagnoses for alcoholism. In addition to
age and sex, we included codes for the following potential risk factors for liver injury as pre-
defined covariates in the PS models (36–38): diabetes, illicit drug use, renal dysfunction,
and drugs with potential for liver damage, defined as those considered category three
hepatotoxic (i.e. clear literature evidence of life-threatening hepatotoxicity or death) in at
least one out of five drug compendia as reported by Guo et al (39). We followed patients
until they experienced acute hepatotoxicity, died, or for a maximum of 60 days. We defined
hepatotoxicity as the occurrence of a diagnostic or procedural code indicating acute liver
injury. These codes have been validated in the context of acetaminophen-induced
hepatotoxicity, with a positive predictive value of 78% (40).
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Active monitoring for rhabdomyolysis among new users of rosuvastatin compared to new
users of atorvastatin
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Active monitoring for diabetes mellitus among new users of rosuvastatin compared to new
users of atorvastatin
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Active monitoring for hepatotoxicity among new users of telithromycin compared to new
users of azithromycin
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